Serum proteome profiles in stricturing Crohn's disease: A pilot study

Inflammatory Bowel Diseases

Volumn 21, Issue 8, 2015, Pages 1935-1941

  Townsend, Peter ^a,b   Zhang, Qibin ^c,d   Shapiro, Jason ^a,b   Webb Robertson, Bobbie Jo ^c   Bramer, Lisa ^c   Schepmoes, Athena A ^c   Weitz, Karl K ^c   Mallette, Meaghan ^b   Moniz, Heather ^b   Bright, Renee ^b   Merrick, Marjorie ^e   Shah, Samir A ^a   Sands, Bruce E ^f   Leleiko, Neal ^a,b  

^a BROWN UNIVERSITY   (United States)

^b HASBRO CHILDREN'S HOSPITAL   (United States)

^c PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^d UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^e Crohn's and Colitis Foundation of America   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical proteomics; Complication; Fibrosis; Intestinal obstruction; Risk assessment; Scarring

Indexed keywords

PEPTIDE; PROTEOME; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISCRIMINANT ANALYSIS; DISEASE REGISTRY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; PARTIAL LEAST SQUARES REGRESSION; PATIENT SELECTION; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SERUM; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; ULCERATIVE COLITIS; ADOLESCENT; BLOOD; CHILD; CONSTRICTION, PATHOLOGIC; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MIDDLE AGED; PHENOTYPE; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; DISCRIMINANT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PILOT PROJECTS; PROGNOSIS; PROTEOME; PROTEOMICS; ROC CURVE; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84946910009     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000445     Document Type: Article

References (45)

1. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43:246-252.
2. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
3. O'Toole A, Korzenik J. Environmental triggers for IBD. Curr Gastroenterol Rep. 2014;16:396.
4. Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5:602-608; quiz 525.
5. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A-36A.
6. Li C, Kuemmerle JF. Mechanisms that mediate the development of fibrosis in patients with Crohn's disease. Inflamm Bowel Dis. 2014;20:1250-1258.
7. Benor S, Russell GH, Silver M, et al. Shortcomings of the inflammatory bowel disease serology 7 panel. Pediatrics. 2010;125:1230-1236.
8. Han NY, Choi W, Park JM, et al. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease. J Dig Dis. 2013;14:166-174.
9. Wilkins MR, Pasquali C, Appel RD, et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (N Y). 1996;14:61-65.
10. Tyers M, Mann M. From genomics to proteomics. Nature. 2003;422:193-197.
11. Wilhelm M, Schlegl J, Hahne H, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509:582-587.
12. Merlos Rodrigo MA, Zitka O, Krizkova S, et al. MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal. 2014;95C:245-255.
13. Han NY, Kim EH, Choi J, et al. Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease. J Dig Dis. 2012;13:497-503.
14. Sands BE, LeLeiko N, Shah SA, et al. OSCCAR: ocean state Crohn's and colitis area registry. Med Health R I. 2009;92:82-85, 88.
15. Wang Y, Yang F, Gritsenko MA, et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics. 2011;11:2019-2026.
16. Sigdel TK, Nicora CD, Hsieh SC, et al. Optimization for peptide sample preparation for urine peptidomics. Clin Proteomics. 2014;11:7.
17. Monroe ME, Shaw JL, Daly DS, et al. MASIC: a software program for fast quantitation and flexible visualization of chromatographic profiles from detected LC-MS(/MS) features. Comput Biol Chem. 2008;32:215-217.
18. LaMarre J, Wollenberg GK, Gonias SL, et al. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991;65:3-14.
19. Adeva M, Gonzalez-Lucan M, Seco M, et al. Enzymes involved in l-lactate metabolism in humans. Mitochondrion. 2013;13:615-629.
20. Tyagi T, Ahmad S, Gupta N, et al. Altered expression of platelet proteins and calpain activity mediate hypoxia-induced prothrombotic phenotype. Blood. 2014;123:1250-1260.
21. Undyala VV, Dembo M, Cembrola K, et al. The calpain small subunit regulates cell-substrate mechanical interactions during fibroblast migration. J Cell Sci. 2008;121:3581-3588.
22. Nauta AJ, Raaschou-Jensen N, Roos A, et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol. 2003;33:2853-2863.
23. Olofsson SO, Wiklund O, Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag. 2007;3:491-502.
24. Tissot JD, Sanchez JC, Vuadens F, et al. IgM are associated to Sp alpha (CD5 antigen-like). Electrophoresis. 2002;23:1203-1206.
25. Ciobanasu C, Faivre B, Le Clainche C. Integrating actin dynamics, mechanotransduction and integrin activation: the multiple functions of actin binding proteins in focal adhesions. Eur J Cell Biol. 2013;92:339-348.
26. Antico G, Aloman M, Lakota K, et al. Uteroglobin, a possible ligand of the lipoxin receptor inhibits serum amyloid A-driven inflammation. Mediators Inflamm. 2014;2014:876395.
27. Berkovits BD, Wolgemuth DJ. The role of the double bromodomain-containing BET genes during mammalian spermatogenesis. Curr Top Dev Biol. 2013;102:293-326.
28. Achour O, Bridiau N, Kacem M, et al. Cathepsin D activity and selectivity in the acidic conditions of a tumor microenvironment: utilization in the development of a novel Cathepsin D substrate for simultaneous cancer diagnosis and therapy. Biochimie. 2013;95:2010-2017.
29. Li N, Zhang Z, Zhang W, et al. Calcineurin B subunit interacts with proteasome subunit alpha type 7 and represses hypoxia-inducible factor-1alpha activity via the proteasome pathway. Biochem Biophys Res Commun. 2011;405:468-472.
30. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr. 2002;22:439-458.
31. Xu ZG, Du JJ, Zhang X, et al. A novel liver-specific zona pellucida domain containing protein that is expressed rarely in hepatocellular carcinoma. Hepatology. 2003;38:735-744.
32. Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost. 2013;11(suppl 1):265-276.
33. Chen CS, Sullivan S, Anderson T, et al. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol Cell Proteomics. 2009;8:1765-1776.
34. Yau Y, Leong RW, Zeng M, et al. Proteomics and metabolomics in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1076-1086.
35. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis. 2009;15:616-629.
36. Vaiopoulou A, Gazouli M, Theodoropoulos G, et al. Current advantages in the application of proteomics in inflammatory bowel disease. Dig Dis Sci. 2012;57:2755-2764.
37. Nanni P, Parisi D, Roda G, et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom. 2007;21:4142-4148.
38. Subramanian V, Subramanian D, Pollok RC. S1182 serum protein signatures determined by mass spectrometry (SELDI-ToF) accurately distinguishes Crohn's disease (CD) from ulcerative colitis (UC). Gastroenterology. 2008;134:A-196.
39. Hatsugai M, Kurokawa MS, Kouro T, et al. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease. J Gastroenterol. 2010;45:488-500.
40. M'Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis. 2011;17:875-883.
41. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433.
42. Meuwis MA, Fillet M, Lutteri L, et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem. 2008;41:960-967.
43. Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl. 2005;44:7342-7372.
44. Paulo JA. Practical and Efficient searching in proteomics: a cross engine comparison. 2013;4:WMCPLS0052.
45. Kim MS, Pinto SM, Getnet D, et al. A draft map of the human proteome. Nature. 2014;509:575-581.